Mirum Pharmaceuticals Inc expected to post a loss of 45 cents a share - Earnings Preview

Mirum Pharmaceuticals

08/11/2024 15:59

* Mirum Pharmaceuticals Inc  MIRM.OQ   MIRM.O  is expected
to show
a rise in quarterly revenue when it reports  results on November
12 for the period ending September 30 2024
    * The Foster City California-based  company is expected to
report
a 71.8% increase in revenue to $82.015 million from $47.73
million a year ago, according to the mean estimate from 9
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Mirum Pharmaceuticals
Inc is
for a loss of 45 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Mirum
Pharmaceuticals Inc is 65.50​, above​ its last closing price
of $41.08. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.47       -0.47      -0.52     Missed  -10.1
 Mar. 31 2024  -0.48       -0.48      -0.54     Missed  -12.7
 Dec. 31 2023  -0.24       -0.24      -0.66     Missed  -171.6
                                                        ​
 Sep. 30 2023  -0.63       -0.63      -0.57     Beat    9.3
 ​​Jun.        -0.81       -0.80      -1.94     Missed  -143.9
 30 2023                                                
 Mar. 31 2023  -0.96       -0.94      -0.80     Beat    14.7​
 Dec. 31 2022  -1.01       -1.02      -0.99     Beat    2.9
 Sep. 30 2022  -1.10       -1.07      -1.02     Beat    4.6
 This summary was machine generated November 8 at 15:59 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)